← All trials
NCT03824925
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2016
- Primary completion
- Oct 18, 2018
- Completion date
- Nov 26, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 70
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Dow University of Health SciencesLead sponsor
- Dow University of Health SciencesReponsible party - principal investigator
- Dow University of Health SciencesOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.